Skin Perfusion Pressure Testing Devices Market Size is set to gain remarkable traction from 2022 to 2028, as skin perfusion pressure tests can be performed on sites with thickened or callused skin and not be affected by moderate or minor edema, among other advantages. In addition, the rising prevalence of peripheral artery disease among adults will further impel industry demand, given the emergence of skin perfusion pressure treatment as an alternative to transcutaneous oxygen monitoring for evaluating capillary blood pressure of the skin. SPP or skin perfusion pressure refers to a non-invasive screening technique of small vessels that has been successfully deployed to assess wound healing potential and determine amputation level. This type of testing is highly beneficial in projecting whether the patient can bear compression therapy for conditions like foot ulcers.
Global burden of chronic diseases like diabetes and the subsequent rise in the incidence of foot ulcers are some of the key trends propelling the skin perfusion pressure testing devices market expansion. Since the lifetime risk for foot ulceration in diabetic patients is 15% to 25%, the need for effective skin perfusion pressure systems is likely to increase considerably. Likewise, the mounting impact of critical limb ischemia in the U.S. will also broaden the scope of the skin perfusion pressure machines over the coming years.
Based on product type, the ultrasound skin perfusion pressure testing devices market will amass considerable gains by 2028. Growth from this segment is driven by the ability of ultrasound to assess structural changes and injury to the soft-tissue structure of the foot. With regards to end-use, the skin perfusion pressure testing devices industry from the ambulatory surgical centers segment is poised to depict a high growth rate through 2028. This growth can be credited to the delivery of cost-effective diagnosis and preventive care services, including orthopedics and pain management, at ASCs.
Asia Pacific skin perfusion pressure testing devices market is likely to register a commendable revenue by 2028, owing to the escalating public healthcare spending in emerging economies. According to the State Council of the People’s Republic of China, the expenditure on public health increased by 15.2% to nearly $293 billion in 2020 as compared to a year earlier, given the onset of the coronavirus crisis. The country is also known for its vast diabetic patient pool with unmet medical needs. These aforesaid factors could amplify the requirement of SPP devices for wound and pressure ulcer management in these patients.
Some of the key players functioning in the skin perfusion pressure testing devices industry are Viasonix, Vasamed, Promed Group, Perimed, Moor Instruments, Koven Technology, ELCAT, CorVascular Diagnostics, and ADInstruments,. These industry participants are implementing various strategies like new product launches, collaborations, business expansions, and acquisitions to strengthen their footprint in the global market.
Delivery of routine medical services has been adversely affected during the novel coronavirus pandemic worldwide. Various physicians postponed outpatient visits for treating chronic diseases such as diabetes during the early months of the crisis. Massive decline in laboratory testing during the initial phase of the pandemic also increased disruptions in diabetes management and glycemic control. Situations such as these may have posed a hindrance to the steady growth of the industry. Development of thrombosis due to hypoxia, hypercoagulability, cytokine release, inflammation, and endothelial dysfunction in COVID-19 patients may, however, aid industry recovery. The thrombotic complications in these patients are also presented with ischemic complications, which could drive the demand for varied testing methods for perfusion pressure in skin among these patients.
Market, By Product Type
Market, By Mode
Market, By End-use
The above information is provided for the following regions and countries: